The drug will be studied in combination with radiologic therapy, and other drugs and biologics in the treatment of solid tumors including esophageal, gastric and pancreatic cancers.
The National Comprehensive Cancer Network (NCCN) will conduct the studies through its oncology research program, which facilitates clinical research by streamlining and centralizing site identification and trial initiation, drawing on the expertise of investigators at NCCN member institutions and helping to establish collaborations with pharmaceutical and biotech companies. Roche will provide support for nine studies at seven NCCN member institutions across the US.
“Financial support from Roche will fund clinical research designed and carried out by investigators at NCCN member institutions – research that may identify treatment advances that can improve both survival and quality of life for patients with difficult-to-treat cancers,” said Dr William McGivney, CEO, NCCN.